Abstract
Glycogen synthase kinase 3 (GSK-3) is a well-known conserved and ubiquitous protein kinase and playing a pivotal role in neurodevelopment, neurogenesis, learning/memory, and neuronal cell death. Dysfunction of GSK-3 had been seen in multiple neurodegenerative and psychiatric diseases. Bipolar disorder and schizophrenia are two common psychiatric diseases first occur in adolescence or young adulthood. They share similar risk genes as well as clinical symptoms, which make it is difficult to be discriminated from each other. Here, by using meta-analysis we reported that glycogen synthase kinase 3β promoter inactive mutant rs334558 may contribute to the development of schizophrenia not bipolar disorder. This might be used to distinguish these two diseases.
Similar content being viewed by others
References
Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276(40):37436–37442
Hoshi M, Takashima A, Noguchi K et al (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA 93(7):2719–2723
Perez-Costas E, Gandy JC, Melendez-Ferro M et al (2010) Light and electron microscopy study of glycogen synthase kinase-3beta in the mouse brain. PLoS One 5(1):e8911
Adachi A, Kano F, Tsuboi T et al (2010) Golgi-associated GSK3beta regulates the sorting process of post-Golgi membrane trafficking. J Cell Sci 123(Pt 19):3215–3225
Bijur GN, Jope RS (2003) Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 14(18):2415–2419
Mukai F, Ishiguro K, Sano Y et al (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81(5):1073–1083
Wexler EM, Geschwind DH (2011) DISC1: a schizophrenia gene with multiple personalities. Neuron 72(4):501–503
Jope RS (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4(2):117–128
Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41:789–813
Detera-Wadleigh SD (2001) Lithium-related genetics of bipolar disorder. Ann Med 33(4):272–285
Gould TD, Manji HK (2002) The Wnt signaling pathway in bipolar disorder. Neuroscientist 8(5):497–511
Manji HK, Moore GJ, Chen G (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46(7):929–940
Valvezan AJ, Klein PS (2012) GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front Mol Neurosci 5:1
Kozlovsky N, Belmaker RH, Agam G (2002) GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur Neuropsychopharmacol 12(1):13–25
Kozlovsky N, Nadri C, Agam G (2005) Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 15(1):1–11
Lovestone S, Killick R, Di Forti M et al (2007) Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30(4):142–149
Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44(7):660–669
Kozlovsky N, Belmaker RH, Agam G (2000) Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157(5):831–833
Benedetti F, Bernasconi A, Lorenzi C et al (2004) A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 355(1–2):37–40
Lin YF, Huang MC, Liu HC (2012) Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord. doi:10.1016/j.jad.2012.08.025
Benedetti F, Poletti S, Radaelli D et al (2010) Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity. Gene Brain Behav 9(4):365–371
Scassellati C, Rotondo A, Bonvicini C et al (2007) Further evidence on the lack of association between glycogen synthase kinase 3beta gene polymorphisms and bipolar disorder. Psychiatr Genet 17(4):249–250
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558
Harris RJ, Bradburn MJ, Deeks JJ et al (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8(1):3–28
Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
Egger M, Davey SG, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
Nishiguchi N, Breen G, Russ C et al (2006) Association analysis of the glycogen synthase kinase-3beta gene in bipolar disorder. Neurosci Lett 394(3):243–245
Szczepankiewicz A, Skibinska M, Slopien A et al (2005) Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology 53(1):51–6
Ikeda M, Iwata N, Suzuki T et al (2005) No association of GSK3beta gene (GSK3B) with Japanese schizophrenia. Am J Med Genet B Neuropsychiatr Genet 134B(1):90–92
Kim T, Song J, Shin Y et al (2004) Association of a polymorphism of glycogen synthase kinase-3 beta (GSK-3 beta) gene and schizophrenia in Korean population. Int J Neuropsychopharmacol 7:S430–S430
Kim YH, Lee JG, Lee SJ (2006) Association study of the glycogen synthase kinase-3 beta (GSK-3 beta)-50T/C polymorphism with schizophrenia; association with depression and cognitive impairment. Eur Neuropsychopharmacol 16:S447–S447
Meng J, Shi Y, Zhao X et al (2008) No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese population. J Psychiatr Res 42(5):365–370
Skibinska M, Kapelski P, Hauser J (2011) Family-based association study of glycogen synthase kinase 3 (GSK3)-beta gene polymorphism in schizophrenia. Eur Neuropsychopharmacol 21:S143–S144
Lee KY, Ahn YM, Joo EJ et al (2006) No association of two common SNPs at position −1727 A/T, -50 C/T of GSK-3 beta polymorphisms with schizophrenia and bipolar disorder of Korean population. Neurosci Lett 395(2):175–178
Szczepankiewicz A, Skibinska M, Hauser J et al (2006) Association analysis of the GSK-3beta T-50C gene polymorphism with schizophrenia and bipolar disorder. Neuropsychobiology 53(1):51–56
Li M, Mo Y, Luo XJ et al (2011) Genetic association and identification of a functional SNP at GSK3beta for schizophrenia susceptibility. Schizophr Res 133(1–3):165–171
Souza RP, Romano-Silva MA, Lieberman JA et al (2008) Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 200(2):177–186
Souza RP, Remington G, Chowdhury NI et al (2010) Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol 20(10):688–694
Hosgood HR, Menashe I, Shen M et al (2008) Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway. Carcinogenesis 29(10):1938–1943
Goodarzi MO, Antoine HJ, Pall M et al (2007) Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. Fertil Steril 87(6):1473–1476
Brunet-Gouet E, Decety J (2006) Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res 148(2–3):75–92
Picchioni MM, Murray RM (2007) Schizophrenia. BMJ 335(7610):91–95
Mcglashan TH, Fenton WS (1991) Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 17(4):609–632
van Os J, Kapur S (2009) Schizophrenia. Lancet 374(9690):635–645
Lymer GK, Job DE, William T et al (2006) Brain–behaviour relationships in people at high genetic risk of schizophrenia. NeuroImage 33(1):275–285
Kircher TT, Thienel R (2005) Functional brain imaging of symptoms and cognition in schizophrenia. Prog Brain Res 150:299–308
Ross CA, Margolis RL, Reading SA et al (2006) Neurobiology of schizophrenia. Neuron 52(1):139–153
Rapoport JL, Addington AM, Frangou S et al (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10(5):434–449
Mao Y, Ge X, Frank CL et al (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136(6):1017–1031
Kieseppa T, Partonen T, Haukka J et al (2004) High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 161(10):1814–1821
Badenhop RF, Moses MJ, Scimone A et al (2002) A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19. Mol Psychiatry 7(6):594–603
Bailer U, Leisch F, Meszaros K et al (2002) Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry 52(1):40–52
Benedetti F, Bollettini I, Barberi I et al (2013) Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology 38(2):313–327
Inkster B, Nichols TE, Saemann PG et al (2009) Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry 66(7):721–728
Acknowledgments
This work was supported in parts by the National Natural Science Foundation of China (31201011), the New Century Excellent Talent of Education Ministry (NCET-10-0421), the Ministry of Science and Technology of China (2011DFG33250).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Hui Tang, Na Shen, and Huijuan Jin contributed equally to this paper.
Rights and permissions
About this article
Cite this article
Tang, H., Shen, N., Jin, H. et al. GSK-3β Polymorphism Discriminates Bipolar Disorder and Schizophrenia: A Systematic Meta-Analysis. Mol Neurobiol 48, 404–411 (2013). https://doi.org/10.1007/s12035-013-8414-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-013-8414-x